Fe-EGCG@RSL3 has a tumor-control effect, and combining intravesical Fe-EGCG@RSL3 therapy with systemic anti-PD1 therapy results in better control of orthotopic bladder tumors (Fig. 6B and C). This evidence concerns the gene PDCD1 and urinary bladder neoplasm.